Verdemed, a Canadian pharmaceutical drug company based on Cannabinoids, acquired the Mydstein laboratory in São Paulo for US $1 million. His plans for the Brazilian market go beyond. The goal is to invest by the end of the year US $10 million to expand the sale of cannabis (medical marijuana) based drugs in the country.
Expansion. With operations in Canada, Chile, Colombia and Brazil, Verdemed intends to join this year in Argentina, Mexico and Peru. Up to 2022, the goal is to invest US $80 million in Latin America.
O Estado de S.Paulo - 23/06/2019
News Item translated automatically
Click HERE to see original
